Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Treace Medical Concepts (TMCI) over the last 6 years, with Q3 2025 value amounting to $2.8 million.

  • Treace Medical Concepts' Capital Expenditures fell 188.61% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year increase of 3181.94%. This contributed to the annual value of $11.6 million for FY2024, which is 117.82% up from last year.
  • Per Treace Medical Concepts' latest filing, its Capital Expenditures stood at $2.8 million for Q3 2025, which was down 188.61% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Treace Medical Concepts' Capital Expenditures ranged from a high of $5.9 million in Q3 2022 and a low of $196000.0 during Q1 2021
  • Its 5-year average for Capital Expenditures is $2.7 million, with a median of $2.8 million in 2025.
  • The largest annual percentage gain for Treace Medical Concepts' Capital Expenditures in the last 5 years was 151896.55% (2021), contrasted with its biggest fall of 7091.99% (2021).
  • Quarter analysis of 5 years shows Treace Medical Concepts' Capital Expenditures stood at $900000.0 in 2021, then surged by 159.11% to $2.3 million in 2022, then dropped by 3.6% to $2.2 million in 2023, then surged by 36.74% to $3.1 million in 2024, then decreased by 8.62% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $4.8 million for Q2 2025, and $3.5 million during Q1 2025.